• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vicarious Surgical Inc.

    7/26/22 4:06:09 PM ET
    $RBOT
    Industrial Specialties
    Health Care
    Get the next $RBOT alert in real time by email
    SC 13G 1 ea163302-13gcadin_vicari.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Vicarious Surgical Inc.

     

    (Name of Issuer)

     

    Class A common stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    92561V109

     

    (CUSIP Number)

     

    July 13, 2022

     

    Date of Event Which Requires Filing of this Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 92561V109

    Page 2 of 7 Pages

         

    1

    Name of Reporting Person:

     

    Cadin Limited

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐ 

    3

    SEC USE ONLY

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    10,426,426 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    10,426,426 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED

     

    10,426,426 (1)(2)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ 

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% (3)

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)On July 13, 2022, D8 Sponsor LLC distributed 100% of the shares of Class A common stock, par value $0.0001 per share, of Vicarious Surgical Inc. (the “Issuer”) held by it to its members in accordance with the terms of its limited liability company agreement. D8 Sponsor LLC distributed 4,090,236 shares of Class A common stock of the Issuer to Cadin Limited in its capacity as a member of D8 Sponsor LLC.

     

    (2)Consists of (i) 4,090,236 shares of Class A common stock of the Issuer held by Cadin Limited and (ii) 6,336,190 shares of Class A common stock of the Issuer underlying warrants held by Cadin Limited which are exercisable within 60 days of the date hereof. Cadin Limited disclaims any beneficial ownership of the securities reported herein except to the extent of any pecuniary interest it may have therein, directly or indirectly.

     

    (3)Based on a total of 107,790,907 shares of Class A common stock outstanding consisting of (i) 101,454,717 shares of Class A common stock outstanding as of May 4, 2022, as reported in the Issuer’s Form 10-Q (File No. 001-39384) filed with the Securities and Exchange Commission on May 9, 2022 and (ii) 6,336,190 shares of Class A common stock of the Issuer underlying warrants held by Cadin Limited which are exercisable within 60 days of the date hereof.

     

     

     

     

    CUSIP No. 92561V109

    Page 3 of 7 Pages

         

    1

    Name of Reporting Person:

     

    Celadon Partners, LLC

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐ 

    3

    SEC USE ONLY

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    10,416,416 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    10,416,416 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED

     

    10,416,416 (1)(2)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ 

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% (3)

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)The securities reported herein are held directly by Cadin Limited. On July 13, 2022, D8 Sponsor LLC distributed 100% of the shares of Class A common stock, par value $0.0001 per share, of Vicarious Surgical Inc. (the “Issuer”) held by it to its members in accordance with the terms of its limited liability company agreement. D8 Sponsor LLC distributed 4,090,236 shares of Class A common stock of the Issuer to Cadin Limited in its capacity as a member of D8 Sponsor LLC. Celadon Partners, LLC is the sole director of Cadin Limited and shares voting and dispositive power over the securities held directly by Cadin Limited. As a result, Celadon Partners, LLC may be deemed to have or share beneficial ownership of the securities held directly by the Cadin Limited.

     

    (2)Consists of (i) 4,090,236 shares of Class A common stock of the Issuer held by Cadin Limited and (ii) 6,336,190 shares of Class A common stock of the Issuer underlying warrants held by Cadin Limited which are exercisable within 60 days of the date hereof. Celadon Partners, LLC disclaims any beneficial ownership of the securities reported herein except to the extent of any pecuniary interest it may have therein, directly or indirectly.

     

    (3)Based on a total of 107,790,907 shares of Class A common stock outstanding consisting of (i) 101,454,717 shares of Class A common stock outstanding as of May 4, 2022, as reported in the Issuer’s Form 10-Q (File No. 001-39384) filed with the Securities and Exchange Commission on May 9, 2022 and (ii) 6,336,190 shares of Class A common stock of the Issuer underlying warrants held by Cadin Limited which are exercisable within 60 days of the date hereof.

     

     

     

     

    CUSIP No. 92561V109

    Page 4 of 7 Pages

     

    SCHEDULE 13G/A

     

    Item 1(a)Name of Issuer:

     

    Vicarious Surgical Inc. (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    78 Fourth Avenue

    Waltham, Massachusetts 02451

     

    Item 2(a)Name of Persons Filing:

     

    This statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    1.Cadin Limited; and

     

    2.Celadon Partners, LLC.

     

    Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

     

    Item 2(b)Address of Principal Business Office, or if None, Residence:

     

    The principal business address of each Reporting Person is as follows:

     

    Suite 2810-12, One Pacific Place

    88 Queensway, Admiralty, Hong Kong

     

    Item 2(c)Citizenship:

     

    See responses to row 4 of the cover page for each Reporting Person.

     

    Item 2(d)Title of Class of Securities: Class A common stock, par value $0.0001 per share

     

    Item 2(e)CUSIP Number: 92561V109

     

    Item 3If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:

     

    (a).☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b).☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c).☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d).☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e).☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f).☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g).☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h).☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i).☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j).☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
    (k).☐ A group, in accordance with Rule 13d-1(b)(1)(ii) (A) through (K).

     

     

     

     

    CUSIP No. 92561V109

    Page 5 of 7 Pages

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4Ownership:

     

    (a).Amount beneficially owned:

     

    See the response to row 9 of the cover page for each Reporting Person.

     


    (b). Percent of class:

     

    See the response to row 11 of the cover page for each Reporting Person.

     


    (c). Number of shares as to which such person has:

     

    (i).Sole power to vote or to direct the vote:

     

    See the response to row 5 of the cover page for each Reporting Person.

     


    (ii). Shared power to vote or to direct the vote:

     

    See the response to row 6 of the cover page for each Reporting Person.

     


    (iii). Sole power to dispose or to direct the disposition of:

     

    See the response to row 7 of the cover page for each Reporting Person

     


    (iv). Shared power to dispose or to direct the disposition of:

     

    See the response to row 8 of the cover page for each Reporting Person.

     

    Item 5Ownership of Five Percent or Less of the Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

     

    Not Applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9

    Notice of Dissolution of Group:

     

    Not Applicable.

     

    Item 10

    Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 92561V109

    Page 6 of 7 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: July 26, 2022
         

    CADIN LIMITED

     

    By:

    Celadon Partners, LLC, its director

         
    By:

    /s/ John Cullinane

     
    Name: 

    John Cullinane

     
    Title: Manager  

     

    CELADON PARTNERS, LLC

     
    By:

    /s/ John Cullinane

     
    Name: 

    John Cullinane

     
    Title: Manager  

     

     

     

     

    CUSIP No. 92561V109

    Page 7 of 7 Pages

     

    EXHIBIT INDEX

     

    Exhibit No.   Exhibit
         
    99.1  

    Joint Filing Agreement.

     

     

     

     

     

    Get the next $RBOT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RBOT

    DatePrice TargetRatingAnalyst
    3/4/2022$16.00 → $7.00Overweight → Neutral
    Piper Sandler
    1/7/2022$16.00Outperform
    Credit Suisse
    12/7/2021$15.00Outperform
    Cowen & Co.
    11/5/2021$15.00Buy
    Canaccord Genuity
    10/18/2021$15.00Buy
    BTIG
    10/7/2021$16.00Overweight
    Piper Sandler
    More analyst ratings

    $RBOT
    Financials

    Live finance-specific insights

    See more
    • Vicarious Surgical Reports First Quarter 2025 Financial Results

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical to Report First Quarter 2025 Financial Results on May 12, 2025

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the first quarter ended March 31, 2025 after the market closes on Monday, May 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 316641. A live and archived webcast of the event will be available at https://investor.v

      4/28/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results

      Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers

      3/17/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

      2/13/24 4:36:42 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

      8/15/23 10:28:36 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

      8/9/23 5:10:57 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Khalifa Sammy sold $1,733 worth of shares (239 units at $7.25), decreasing direct ownership by 0.67% to 35,630 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/4/25 2:16:21 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • CEO Sachs Adam David sold $3,343 worth of shares (463 units at $7.22), decreasing direct ownership by 0.90% to 50,723 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/4/25 2:16:05 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Chief Technology Officer Khalifa Sammy sold $4,912 worth of shares (653 units at $7.52), decreasing direct ownership by 2% to 35,869 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      5/21/25 1:19:38 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    SEC Filings

    See more
    • Vicarious Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vicarious Surgical Inc. (0001812173) (Filer)

      5/12/25 7:47:13 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Vicarious Surgical Inc.

      10-Q - Vicarious Surgical Inc. (0001812173) (Filer)

      5/12/25 5:00:42 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by Vicarious Surgical Inc.

      144 - Vicarious Surgical Inc. (0001812173) (Subject)

      5/1/25 4:48:24 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vicarious Surgical downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously

      3/4/22 4:51:18 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Credit Suisse initiated coverage on Vicarious Surgical with a new price target

      Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00

      1/7/22 7:09:02 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Cowen & Co. initiated coverage on Vicarious Surgical with a new price target

      Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00

      12/7/21 7:31:51 AM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

      RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company's Board of Directors, effective May 22, 2025. "We are delighted to welcome Dr. Carr-Brendel to Glucotrack's Board of Directors," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. "With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monito

      5/28/25 8:30:00 AM ET
      $GCTK
      $RBOT
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Vicarious Surgical Reports First Quarter 2025 Financial Results

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Announces New Collaboration with UMass Memorial Medical Center

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed an agreement with UMass Memorial Medical Center intended to support adoption and utilization of its robotic system through enhanced perioperative practices, surgeon education and other engagement strategies. UMass Memorial Medical Center, the flagship academic medical center of UMass Memorial Health, is the largest not-for-profit hospital in Central Massachusetts with 826 licensed beds and the clinical partner of the University of Massachusetts Chan Medical School. UMass Memorial Health is committed to prov

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

      Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

      3/13/25 8:30:00 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

      1/29/24 8:30:00 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Announces Changes to Board of Directors

      Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari

      1/23/23 4:10:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care